^
    Back
    Association details:
    Biomarker:ANGPT2 expression
    Cancer:Renal Cell Carcinoma
    Drug:Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Br J Cancer
    Title:

    Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma

    Published date:
    10/07/2020
    Excerpt:
    The 5-factor PFS-CBS was comprised of HGF, MIG, IL-18BP, IL-18, and ANG-2 and the 5-factor OS-CBS included TIMP-1, M-CSF, IL-18BP, ANG-2 and VEGF….Multivariate Cox regression analyses indicated that the CBS-high group was predictive of a longer PFS and OS with lenvatinib-plus-everolimus versus lenvatinib (Pinteraction = 0.0070 and Pinteraction = 0.0377, respectively) but not versus everolimus (Pinteraction = 0.2297 and Pinteraction = 0.2125, respectively).
    Secondary therapy:
    everolimus
    DOI:
    10.1038/s41416-020-01092-0
    Trial ID:
    NCT01136733